Dr. Laura Mc Cullagh
Adjunct Assistant Professor, Pharmacology & Therapeutics
Dr Laura McCullagh is Associate Professor of Pharmacoeconomics & Health Technology Assessment. Dr McCullagh is a graduate from the Sunderland School of Pharmacy (First Class Hons). She holds a PhD for her research which focused on Health Technology Assessment within the Irish Healthcare Setting.
Dr McCullagh is a member of the National Centre for Pharmacoeconomics (NCPE) Review Group. She has been the lead author on over 30 reports detailing the Health Technology Assessment of drugs submitted to the NCPE for evaluation prior to a reimbursement decision being made by the HSE. Dr McCullagh is a member of the National Cancer Control Programme (NCCP) Technology Review Group.
Previous roles have included HRB ICE Research Fellow, Chief Pharmacist in St James's Hospital, Dublin and Senior Medicines Information Pharmacist, Oxford Radcliffe Trust, UK.
Publications and Further Research Outputs
Gorry, Claire and Leahy, Joy and Lamrock, Felicity and Walsh, Cathal and White, Arthur and Barry, Michael and McCullagh, Laura, VP82 Impact of Evidence Synthesis Methods on Outcome of Economic Evaluation, International Journal of Technology Assessment in Health Care, 35, (S1), 2019, p93 - 94
Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. , Neoadjuvant Treatment for malignant and metastatic melanoma. , Cochrane Database of Systematic Reviews. , (3), 2018
Cardwell K, Clyne B, Moriarty F, Wallace E, Fahey T, Boland F, McCullagh L, Clarke S, Finnigan K, Daly M , Barry M, Smith, S , Supporting prescribing in Irish primary care: Protocol for a non-randomised pilot study of a general practice pharmacist (GPP) intervention to optimise prescribing in primary care., Pilot and Feasibility Studies, 4, (122), 2018
McCullagh L, Schmitz S, Barry M, Walsh C, Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer, PharmacoEconomics, 2017
Corcoran A, Hickey N, Barry M, Usher C, McCullagh L, Ivacaftor for cystic fibrosis; An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting., Irish Medical Journal, 110, (8), 2017
Spillane S, McCullagh L, Barry M, Usher C, Analysis of Pharmacy Claims for High Cost Oncology Products: Abiraterone and Enzalutamide Usage in Mcrpc in Ireland, Value Health, 19, (7), 2016, ppA754 - A754
Ermisch M, Bucsics A, Vella Bonanno P, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogene E, Fürst J, Garuolien" K, van der Graaff M, Gulbinovi" J, Haycox A, Jones J, Joppi R, Laius O, Langner I, Martin AP, Markovic-Pekovic V, McCullagh L, Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways., 2016
Morgan RB, McCullagh L, Barry M, Daly C, The cost of inpatient management of heart failure patients: a microcosting study in the Irish healthcare setting., 2016
O'Donnell H, McCullagh L, Barry M, The Potential Budget Impact of PCSK9 Inhibitors in Ireland, Value Health, 2016, 7, (19), 2016, ppA643 - A643
Schmitz S, McCullagh L, Dolan E, Walsh C, The Quev Score: A Quantitative Evaluation of the Quality of Clinical Evidence in HTA, Value Health, 19, (7), 2016, ppA499 - A499
Schmitz S, McCullagh L, Adams R, Walsh C, Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland, PharmacoEconomics, 2016
Gorry C, McCullagh M, Barry M, Drug Utilisation of Braf Inhibitors for Melanoma in Ireland, Value Health, 19, (7), 2016, ppA728 - A728
Dolan E, Schmitz S, Barry M, McCullagh L, Movement of Drugs for Cancer Through The Pharmacoeconomic Evaluation Process in Ireland: Consideration Given to The Quality of Clinical Evidence, Value Health, 2016, 19, (7), 2016, ppA757 - A757
McCullagh L, Barry M, The Pharmacoeconomic Evaluation Process in Ireland, PharmacoEconomics, 34, (12), 2016, p1267 - 1276
Godman B, Malmström RE, Diogene E, Gray A, Jayathissa S, Timoney A, Acurcio F, Alkan A, Brzezinska A, Bucsics A, Campbell SM, Czeczot J, de Bruyn W, Eriksson I, Yusof FA, Finlayson AE, Fürst J, Garuoliene K, Guerra Júnior A, Gulbinovi, J, Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?, 2015
McCullagh L, Adams R, Barry M, Schmitz S, Walsh C, Evaluation Of 'Real-World' Ipilimumab Data In Ireland., Value Health, 18, (7), 2015, ppA441-A441-
McCullagh LM, Tilson L, Adams R, Barry M, HTA Informed Price Negotiations: Cost Savings To The Health Payer in Ireland., 2014
O'Brien C, Fogarty E, Walsh C, Dempsey O, Barry M, Kennedy MJ, McCullagh L, The cost of the inpatient management of febrile neutropenia in cancer patients - a micro-costing study in the Irish healthcare setting. , European Journal of Cancer Care, 2014
McCullagh L, Barry M., Survival analysis used in company submissions to the National Centre for Pharmacoeconomics, Value Health, 16, (7), 2013, ppA398 - A398
Adams R, Gray E, McCullagh L, Schmitz S, Barry M, Walsh C, Budget impact and thresholds: how are real decisions made? Expected utility or Prospect Theory, Value Health, 16, (7), 2013, ppA490 - A490
Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Personalizing health care: feasibility and future implications., 2013
Schmitz S, McCullagh L, Adams R, Barry M, Walsh C, A retrospective analysis of drug reimbursement decisions in Ireland. A multi criteria decision analysis approach., Value Health, 2013, 16, (7), 2013, ppA465 - A465
Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, Brzezinska A, Bucsics A, Campbell S, Ferrario A, Finlayson AE, Fürst J, Garuoliene K, Gomes M, Gutiérrez-Ibarluzea I, Haycox A, Hviding K, Herholz H, Hoffmann M, Jan S, Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs., 2013
McCullagh L, Walsh C, Barry M , Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting., PharmacoEconomics, 30, (10), 2012, p941 - 959
McCullagh L, Barry M, Prescribing trends for dabigatran etexilate in primary care., 2012
McCullagh L, Walsh C, Barry M, Integration of value of information into the decision making process in Ireland, Value Health, 15, (7), 2012, ppA317 - A317
McCullagh L, Usher C, Barry M, A review of the primary care prescribing of dabigatran etexilate and rivaroxaban in Ireland, Value Health, 14, (7), 2011, ppA390 - A390
McCullagh L, Walsh C, Barry M, Prioritizing further research using the expected value of perfect information: application to VTE prophylaxis post total hip replacement, Value Health, 13, (7), 2010, ppA359 - A359
McCullagh L, Tilson L, Walsh C, Barry M, A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting., 2009
McCullagh L, Tilson L, Walsh C, Barry M, Cost effectiveness of rivaroxaban and dabigatran etexilate for the prophylaxis of venous thromboembolism and associated long term compliactions post total hip replacement in Ireland, Value Health, 12, (7), 2009, ppA334 - A334
Hopkins S, Lambourne J, Farrell G, McCullagh L, Hennessy M, Clarke S, Mulcahy F, Bergin C., Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals., HIV Med. , 7, (4), 2006, p248-54.
Clarke S, Delamere S, McCullough L, Hoskins S, Bergin C, Mulcahy F, Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users, HIV Med, 4, (1), 2003, p33 - 37
DescriptionResearch interests include health technology assessment, pharmacoeconomic evaluation, value of information analysis, multiple criteria decision analysis, survival analysis, cost of care studies and analysis of drug utilisation and expenditure in the real world setting. Dr McCullagh is a co-applicant on a number of on-going grants. A Health Research Board (HRB) Applied Partnership Award examines how analysis of drug utilisation and real world outcomes databases can support pharmacoeconomic evaluations. A HRB RCQPS Award investigates how a GP practice-based Pharmacist Medicines Optimisation Programme might support prescribing in Irish primary care. A further HRB RCQOS Award investigates how a multi-disciplinary prescribing strategy might support appropriate prescribing of oral nutritional supplements by Irish GPs. Dr McCullagh has published widely in peer reviewed journals and has presented her research at National, European and International Conferences. She has provided peer-review for a number of journals including Value in Health, PharmacoEconomics, The European Journal of Health Economics, Thrombosis and Haemostasis, Journal of Hospital Medicine, Cost Effectiveness and Resource Allocation. She has also provided peer-review for the Innovational Research Incentive Scheme - Veni, Netherlands Organisation for Scientific Research. Dr McCullagh supervises PhD candidates, MSc candidates, post-doctoral researchers and undergraduate medical students in the attainment of their research.
Member of the National Centre for Pharmacoeconomics (NCPE)Technology Review Group
Member of the National Cancer Control Programme (NCCP) Technology Review Group
Awards and Honours
'Murdoch McKenzie' Prize for Highest Academic Grades in Pharmacy Undergrad Degree (1989-1991 inclusive), University of Sunderland, UK.
'Mawson Proctor' Award for Highest Academic Grades in Pharmaceutical Chemistry & Pharmacognosy (Pharmacy), University of Sunderland, UK.
'Boots' The Chemist Prize, for Highest Academic Grades in First Year of Pharmacy Undergrad Degree, University of Sunderland, UK.
Member of The Pharmaceutical Society of Ireland.
Member of The Royal Pharmaceutical Society of Great Britain.